Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.
Location: United States, California, San Carlos
Investors 4
Date | Name | Website |
21.07.2020 | Y Combinat... | ycombinato... |
10.02.2022 | MBC BioLab... | mbcbiolabs... |
12.06.2021 | Creative D... | creativede... |
- | Tachyon Ve... | tachyon.vc |
Mentions in press and media 2
Date | Title | Description | Source |
17.03.2020 | All the companies from Y Combinator’s W20 Demo Day, Part IV:... | Y Combinator’s Demo Day was a bit different this time around. As concerns grew over the spread of C... | techcrunch... |
- | Altay Therapeutics | “Home | Altay Tx” | fastfounde... |